A Study to Evaluate Satisfaction With Care in Patients With Cancer Receiving Immunotherapy Treatment at Home

Bristol-Myers Squibb (BMS)

Status: Completed

Conditions: Cancer; Solid Tumors

Treatments: Drug: Immunotherapy

Study type: Observational

Funder types: Industry

Identifiers

NCT06163053

CA209-6JE

Details and patient eligibility

About

The purpose of this observational study in France is to evaluate changes in satisfaction with care in participants with solid tumors who transitioned from receiving immunotherapy treatment in the hospital outpatient setting to receiving treatment at home

Enrollment: 49 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Male or female ≥ 18 years old
• Participants whose oncology specialist has already initiated treatment with immune checkpoint inhibitors (ICIs) in the outpatient hospital setting for an advanced solid tumor (as monotherapy or in combination) or as adjuvant therapy, in an indication approved and reimbursed in France
• Participants whose oncology specialist has independently of the study defined their eligibility for hospital at home (HAH) before contacting the HAH unit for final admission
• Participants who provide oral informed consent to participate in the study

Exclusion criteria

• Participants who have expressed an opposition to their data collection
• Participants under guardianship
• Participants taking part in an interventional study for cancer treatment with at least one ICI as an investigational drug

Trial design

49 participants in 1 patient group

Participants receiving immunotherapy at home

Treatment:

Drug: Immunotherapy